{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:03:56Z","timestamp":1769753036380,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jcyt.2024.12.009","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T12:39:19Z","timestamp":1735821559000},"page":"534-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enrichment of CD4+ and CD8+ T lymphocytes with a column-free flow-based device for clinical cell manufacturing"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0334-1391","authenticated-orcid":false,"given":"Paulina","family":"Langa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Sellers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Placencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Fick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silin","family":"Sa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2272-0298","authenticated-orcid":false,"given":"Ignacio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amittha","family":"Wickrema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcyt.2024.12.009_bib0001","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"issue":"303","key":"10.1016\/j.jcyt.2024.12.009_bib0002","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2024.12.009_bib0003","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jcyt.2024.12.009_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1007042","article-title":"CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production","volume":"13","author":"Abraham-Miranda","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2024.12.009_bib0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.009_bib0006","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.009_bib0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2024.12.009_bib0008","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jcyt.2024.12.009_bib0009","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcyt.2024.12.009_bib0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"10.1016\/j.jcyt.2024.12.009_bib0011","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jcyt.2024.12.009_bib0012","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jcyt.2023.07.012","article-title":"Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform","volume":"25","author":"Trainor","year":"2023","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.jcyt.2024.12.009_bib0013","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1080\/08830185.2022.2067154","article-title":"Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies","volume":"41","author":"Song","year":"2022","journal-title":"Int Rev Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2024.12.009_bib0014","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2024.12.009_bib0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/10408363.2019.1633512","article-title":"Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects","volume":"56","author":"Poorebrahim","year":"2019","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"9","key":"10.1016\/j.jcyt.2024.12.009_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005189","article-title":"Automated, scaled, transposon-based production of CAR T cells","volume":"10","author":"Lock","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2024.12.009_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jcyt.2024.12.009_bib0018","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2024.12.009_bib0019","unstructured":"CliniMACS\u00ae Plus Instrument User Manual Software version 2.4x Issued: 2022-11 210-003-188\/02; User manual for CliniMACS Plus Instrument (CE), software version 2.4x, English (miltenyibiotec.com)."},{"key":"10.1016\/j.jcyt.2024.12.009_bib0020","unstructured":"CliniMACS Prodigy\u00ae User Manual (U.S. Edition) Issued: 2021-06 38401\/03; CliniMACS Prodigy User Manual (U.S. Edition) (miltenyibiotec.com)."},{"issue":"3","key":"10.1016\/j.jcyt.2024.12.009_bib0021","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jcyt.2021.11.004","article-title":"Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use","volume":"24","author":"Gotti","year":"2022","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.009_bib0022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.12.009_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma","volume":"12","author":"Mart\u00ednez Bedoya","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jcyt.2024.12.009_bib0024","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8+T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.jcyt.2024.12.009_bib0025","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.jcyt.2024.12.009_bib0026","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1182\/bloodadvances.2021006293","article-title":"Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL","volume":"6","author":"Talleur","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jcyt.2024.12.009_bib0027","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","article-title":"CAR-T cell therapy: where are we now, and where are we heading?","volume":"5","author":"Wang","year":"2023","journal-title":"Blood Sci"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:09:19Z","timestamp":1762546159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924009666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1465324924009666"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.12.009","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enrichment of CD4+ and CD8+ T lymphocytes with a column-free flow-based device for clinical cell manufacturing","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}